Marissa Casillo
Family · Foxborough, MANPI 1972251817
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by TG Therapeutics, Inc. at 31.7% of the total. 2025 is the largest year on record at $22,113, more than ten times the $1,109 reported in 2022. Among family clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $60.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$10K
- Pfizer$7K
- AbbVie$4K
- Lundbeck LLC$2K
- EMD Serono, Inc.$2K
- SK Life Science, Inc.$789
- plus $6K from 42 others
What the payments were for
- Consulting fees$2,4608%
- Speaking & faculty fees$15,20649%
- Travel & lodging$1,1284%
- Food & beverage$12,16539%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,017 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 13 | $158,316 |
| Nurtec OdtRimegepant Sulfate | 92 | $152,010 |
| TecfideraDimethyl Fumarate | 14 | $132,889 |
| Kesimpta PenOfatumumab | 15 | $130,614 |
| UbrelvyUbrogepant | 109 | $119,191 |
| BetaseronInterferon Beta-1b | 12 | $111,508 |
| QuliptaAtogepant | 46 | $62,652 |
| Emgality PenGalcanezumab-Gnlm | 65 | $49,053 |
| Glatiramer Acetate | 13 | $37,034 |
| BotoxOnabotulinumtoxina | 16 | $20,003 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $18,145 |
| Dalfampridine ErDalfampridine | 65 | $17,555 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $12,135 |
| Sumatriptan Succinate | 38 | $3,512 |
| Baclofen | 69 | $1,912 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $3,991 | $201,846171 claims |
| EMD Serono, Inc.Rebif | $2,001 | $158,31613 claims |
| PfizerNurtec Odt | $6,687 | $152,01092 claims |
| BiogenTecfidera | $727 | $132,88914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Foxborough
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
- Rochelle NazarianDanvers$31K
- Yelena KiselWorcester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.